

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

VOLUNTARY ANNOUNCEMENT

FORMATION OF A JOINT VENTURE

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on 13 April 2026 (after trading hours), Shenzhen Zhong Ji Health Science Company Limited* (深圳市中基健康科學有限公司) (“**Zhong Ji Health**”, a wholly-owned subsidiary of the Company) has entered into a joint venture agreement (the “**JV Agreement**”) with Guangdong Liangjingjing Technology Company Limited* (廣東亮睛睛科技有限公司) (“**Liangjingjing**”) in relation to the establishment of a joint venture (the “**Joint Venture**”) in the People’s Republic of China (the “**PRC**”), which, upon establishment, will be owned as to 51% by Zhong Ji Health and 49% by Liangjingjing. The Joint Venture will be engaged in the provision of AI-powered vision health and longevity products and services globally, building the world’s first AI+ vision health ecosystem platform.

The Joint Venture will have an initial registered capital of RMB1,000,000, which will be contributed by Zhong Ji Health and Liangjingjing in proportion to their respective interest in the Joint Venture. The capital contribution will be mainly utilised as working capital of the Joint Venture. The Group will finance its capital commitment from its internal resources and in completing its registration process with the PRC Industry and Commerce Bureau.

INFORMATION ON THE PARTIES TO THE JV AGREEMENT

The Company is a company incorporated in Bermuda with limited liability and is an investment holding company which, through its subsidiaries, is principally engaged in the business of longevity science business, money lending, financial and investment advisory, as well as securities, property and investments. Zhong Ji Health is a company established in the PRC with limited liability and is principally engaged in the provision of health longevity management service as well as the manufacturing and sales of health longevity products.

Liangjingjing is a limited company established in the PRC in 2023. Liangjingjing is a high-tech, innovative company specialising in AI+ eye health. Liangjingjing brings together a number of renowned academicians and top experts in this field, possessing strong scientific research capabilities and profound technical expertise. It holds significant professional influence and core competitiveness within the industry, focusing on the research and development of AI-powered eye health large language models, cutting-edge AI-driven optic nerve and visual technology, and smart vision training equipment, as well as comprehensive management in the field of visual health. Drawing on the latest technologies from the US, Germany and Japan, Liangjingjing provides precise, intelligent solutions and product experiences for a wide range of vision problems, building an AI-powered eye health technology platform.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, Liangjingjing and its ultimate beneficial owner(s) are independent of and not connected with the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company as at the date of this announcement.

BENEFITS OF AND REASONS FOR ENTERING INTO THE JV AGREEMENT

The Group is principally engaged in the provision of health longevity management service as well as the production and sales of health longevity products through its subsidiary, namely Zhong Ji Health. The Board believes that the health longevity science market has tremendous promising prospects, as global consumers are placing increasing importance on health management and quality of longevity. With a growing demand for improving overall well-being, enhancing immune functions, delaying physiological aging, and maintaining youthful vitality, the industry is presented with boundless prospects for development.

The formation of the Joint Venture is in line with the Group's longevity science business development strategies and plans, which will be conducive to the future business development of the Group. The Joint Venture is committed to building the world's first AI+ eye health ecosystem platform, focusing on the research, development, production and omnichannel marketing of AI-driven eye care products. Building on its flagship products — including the world's only AI-powered vision-correcting glasses, IPS exosome eye drops and the lutein range — the company is to create a closed-loop, end-to-end AI eye health ecosystem, thereby establishing itself as a leading brand in the global field of technology-driven eye care. The Board believes that the JV Agreement will further improve the Group's presence in the field of longevity science, and explore new longevity science revenue stream for the Company with a view to bringing a more stable and sustainable revenue growth to the Group in the long run.

The terms of the JV Agreement were negotiated between the parties thereto after arm's length negotiations. In light of the above, the Board is of the view that the terms of the JV Agreement are fair and reasonable and in the interests of the Company and its shareholders as a whole.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 13 April 2026

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Li Xiaoshuang

Non-executive Directors

Dr. He Yiwu
Mr. Lyu Changsheng

Independent Non-executive Directors

Mr. Huang Jiang
Prof. Huang Cibo
Ms. Wang Huijuan
Ms. Tam Mei Chu

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.

* *For identification purposes only*